Latest Atherosclerosis Stories
The medical world is excited about the potential that stem cells have demonstrated in aiding the recovery of patients who have suffered a heart attack.
Two New Research Studies Provide Further Support for the Potential Role of CSL112 in the Reduction of Early Recurrent Cardiovascular Events following Myocardial Infarction KING OF
The Heart Attack Eradication Society Urges Doctors to Adopt Personalized Risk Assessment. Houston, TX (PRWEB) November 12, 2014 Leading preventive cardiologists
CSL112 Represents a Promising Investigational Therapy That May Fill a Void in Reducing Early Recurrent Cardiovascular Events in Patients Who Have Suffered a Heart Attack KING OF PRUSSIA, Pa.,
~Data to be presented at the American College of Rheumatology Annual Meeting CHARLOTTESVILLE, Va., Nov.
LA JOLLA, Calif., Oct.
TEL-AVIV, Israel, Sept. 29, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.
Imaging can be a cost-effective way to identify people at risk for stroke who might benefit from aggressive intervention, according to a new modeling study published online, September 16, in the
NuvOx Pharma has been awarded a Phase I Small Business Innovative Research contract (contract # HHSN268201400045C) for “Development of Molecular Imaging Agents and Methods to Detect High Risk
- A transitional zone between two communities containing the characteristic species of each.